# Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

> **NCT04678921** · PHASE1 · COMPLETED · sponsor: **I-Mab Biopharma US Limited** · enrollment: 16 (actual)

## Conditions studied

- Solid Tumor
- Metastatic Cancer
- Advanced Cancer

## Interventions

- **DRUG:** TJ210001

## Key facts

- **NCT ID:** NCT04678921
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678921, "Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04678921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*